Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genome-wide association study identifies and validates genetic variation in the RIG-I/MAVS signaling pathway associated with HIV-related Kaposi sarcoma in children and adults.

Frontiers in oncology·2026

Same author

Pathogenic myeloid phenotypes drive disease pathology in a novel human neurohistiocytosis model.

Blood·2026

Same author

Incidence of Cancers Among Children Living With HIV in Malawi After Widespread Availability of Antiretroviral Therapy: A Population-Based Study.

JCO global oncology·2026

Same author

Distinct EBV-Associated Phenotypes Due to a Novel Homozygous Missense Variant in CD27.

bioRxiv : the preprint server for biology·2026

Same author

Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.

Blood advances·2026

Same author

Pediatric hemophagocytic lymphohistiocytosis: current conceptualization, diagnosis, and treatment.

Blood·2026

Search research articles

Related Experiment Video

Updated: Dec 27, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Langerhans cell histiocytosis.

Carlos Rodriguez-Galindo^1,2, Carl E Allen³

¹Department of Global Pediatric Medicine and.

|February 28, 2020

Summary

Langerhans cell histiocytosis (LCH) involves abnormal cell growth, often linked to MAPK pathway activation. Targeted BRAF/MEK inhibitors show promise for relapsed LCH, but cure potential is still under investigation.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Dec 27, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

Oncology
Immunology
Genetics

Background:

Langerhans cell histiocytosis (LCH) arises from clonal myeloid precursor expansion.
Pathogenic cells exhibit constitutive MAPK signaling pathway activation.
LCH presents with diverse organ involvement and potential for significant morbidity.

Purpose of the Study:

To review current understanding and treatment strategies for LCH.
To evaluate emerging therapies for relapsed and refractory LCH.
To highlight challenges in LCH management, including reactivation and treatment failure.

Main Methods:

Review of existing literature on LCH pathogenesis and treatment.
Analysis of clinical responses to MAPK pathway inhibitors in LCH.
Assessment of survival rates and long-term outcomes in LCH patients.

Main Results:

LCH treatment is risk-adapted, with varying outcomes based on organ involvement.
Disease reactivation occurs in over 30% of patients, necessitating effective second-line therapies.
BRAF and MEK inhibitors demonstrate promising initial responses in refractory LCH cases.

Conclusions:

While survival is good for patients without organ dysfunction, mortality reaches 20% with organ involvement.
Effective second-line treatments are needed due to high reactivation rates.
Targeted therapies like BRAF/MEK inhibitors offer new hope but require further study for curative potential.